III. Instantaneous inhibition by compound 48/80 of tissue factor-initiated extrinsic coagulation is mediated by the downregulation of factor VII activation.
Our previous study has demonstrated a unique biological function of compound 48/80 (48/80) in the downregulation of monocytic tissue factor (TF)-initiated hypercoagulation in response to bacterial endotoxin (lipopolysaccharide, LPS) [A. J. Chu et al. (1999) Biochim. Biophys. Acta 1472, 386-395]. The inhibition was not due to the blockade of LPS cell signaling as evidenced by the unaffected LPS-induced TF synthesis. In the present study, we investigate the direct inhibitory action of 48/80 on the extrinsic coagulation cascade. TF-initiated coagulation was assayed by a single-stage clotting assay. Chromogenic assays dissected the extrinsic pathway to measure the activities of FVII, FX, and prothrombin by monitoring the hydrolyses of nitroaniline-conjugated substrates, identifying the inhibitory site(s). We report that 48/80 in vitro instantaneously inhibited rabbit brain thromboplastin (rbTF)-initiated coagulation in a dose-dependent manner. 48/80 preferentially inhibited FVII activation without any detectable effect on FVIIa, FXa, and thrombin activities. Neither FX activation nor prothrombin activation was affected. The significant inhibition on FVII activation was found to be noncompetitive with a fourfold reduction in the apparent Vmax of FVIIa formation from 7.1 to 1.7 nM/min, while the apparent Km (approximately 365 nM) remained unaffected. Western blotting analysis further confirmed that FVIIa formation derived from FVII was significantly diminished by 48/80, which was accompanied by blocked FVII binding to rbTF. In conclusion, 48/80 readily blocked FVII binding to rbTF, leading to diminished FVII activation and FVIIa formation. As a result, TF-initiated extrinsic coagulation was downregulated.
Chu
A J
AJ
Department of Surgery, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA. ad5742@wayne.edu
Wang
Z G
ZG
Fox
M J
MJ
D000818:Animals; D001921:Brain / Q000378:metabolism; D004151:Dipeptides / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D005167:Factor VII / Q000378:metabolism*; D015951:Factor Xa / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D008024:Ligands; D009842:Oligopeptides / Q000378:metabolism; D011817:Rabbits; D013925:Thromboplastin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013997:Time Factors; D003189:p-Methoxy-N-methylphenethylamine / Q000737:chemistry / Q000494:pharmacology*
D004151:Dipeptides; D008024:Ligands; D009842:Oligopeptides; D003189:p-Methoxy-N-methylphenethylamine; C015608:benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide; C021129:S 2238; C041319:isoleucyl-prolyl-arginine-4-nitroanilide; D005167:Factor VII; D013925:Thromboplastin; D015951:Factor Xa